Search ABT
ABBOTT LABORATORIES
NYSE · CIK 1800
Last close97.5
Daily change+0.81 (0.84%)
10 Years gain+169.87%
Dividends TTM2.48 (+6.90%)
Dividend yield2.56%
Fundamental Analysis
ABT · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
37.0Momentum
50.4Acceleration
43.8Confidence
91.0Annual Revenue19
Quarterly Revenue84
Annual CFO15
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth6.2 / 25
Quality12.8 / 25
Capital Efficiency3.0 / 20
Balance Sheet4.3 / 15
Shareholder Economics8.8 / 10
Forward Indicators0.0 / 5
Signals
Gross margin expansionGross margin improved by 1.0141 percentage points.
Operating leverageOperating margin improved by 0.08 percentage points.
Share count reductionDiluted share count declined 0.03%.
Strong operating leverageOperating income is growing faster than revenue while operating margin expands.
Warnings
ROIC declining · MEDIUMROIC declined by 3.2123 percentage points.
Key Metrics
Revenue Growth TTM9.78%OK
Revenue CAGR 3Y0.51%OK
Gross Margin56.2%OK
Operating Margin16.23%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC8.76%OK
Incremental Operating Margin 3Y-133.4%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y-0.03%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $44.33B | $25.01B | $8.05B | $9.57B | $7.40B | 56.42% | 18.17% | 16.68% | 11.29% | 1.75B |
| 2025 FY Dec 31, 2024 | $41.95B | $23.24B | $6.83B | $8.56B | $6.35B | 55.41% | 16.27% | 15.14% | 8.89% | 1.75B |
| 2025 FY Dec 31, 2023 | $40.11B | $22.13B | $6.48B | $7.26B | $5.06B | 55.18% | 16.15% | 12.61% | 12.46% | 1.75B |
| 2024 FY Dec 31, 2022 | $43.65B | $24.51B | $8.36B | $9.58B | $7.80B | 56.15% | 19.16% | 17.88% | 16.07% | 1.76B |
| 2023 FY Dec 31, 2021 | $43.08B | $24.54B | $8.43B | $10.53B | $8.65B | 56.97% | 19.56% | 20.08% | 16.53% | 1.79B |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $44.03B | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-028357, 0001628280-25-036720 |
| Revenue Growth TTM | 9.78% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-028357, 0001628280-25-036720 |
| Revenue CAGR 3Y | 0.51% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-010185 |
| Revenue CAGR 5Y | 5.08% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-010185 |
| Gross Profit CAGR 3Y | 0.67% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-010185 |
| Operating Income Growth | 10.33% | OperatingIncome_current / OperatingIncome_prior_year - 1 | OK | 0001628280-26-028357, 0001628280-25-036720 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 56.2% | Gross Profit / Revenue | OK | 0001628280-26-028357, 0001628280-25-036720 |
| Operating Margin | 16.23% | Operating Income / Revenue | OK | 0001628280-26-028357, 0001628280-25-036720 |
| ROIC | 8.76% | NOPAT / Average Invested Capital | OK | 0001628280-26-028357, 0001628280-25-036720 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-028357 |
| Current Ratio | 1.39x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.21x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-028357 |
| Revenue per Diluted Share | $25.20 | Revenue / Diluted Shares | OK | 0001628280-26-028357, 0001628280-25-036720 |